Tiotropium is efficacious in 6–17-year-olds with asthma, independent of T2 phenotype

ConclusionsThis exploratory analysis suggests that improvements with tiotropium as add-on to ICS, with or without additional controllers, in 6–17-year-olds with symptomatic asthma do not vary according to systemic markers of T2 inflammation, namely total IgE and blood eosinophil counts.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research